Abstract Number: PO140
Meeting: ISTH 2021 Congress
Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical
Background: The hospital utilization and medical resource usage of hemophilia patients is closely related to the burden on China’s healthcare system.
Aims: This study was based on a single center in China and was conducted to comprehensively assess the hospitalization factors of hemophilia A or B patients.
Methods: We retrospectively analyzed clinical characteristics, diagnosis, inhibitor status, causes and duration of hospitalizations and medical costs of 323 hospitalizations in which hemophilia must be considered as the main cost factor during hospitalization from January 2009 to December 2020 from the Institute of Hematology and Blood Diseases Hospital in Tianjin, China. Non-parametric statistics were used and P<0.05 was considered statistically significant.
Results:
| Severe hemophilia without inhibitor | Moderate or mild hemophilia without inhibitor | Inhibitor patients | Total | |
| Minor bleed | 62 | 164 | 72 | 298 |
| Major bleed | 10 | 28 | 15 | 53 |
| Pseudotumor | 2 | 9 | 3 | 14 |
| Surgery | 0 | 9 | 1 | 10 |
| Other | 9 | 9 | 6 | 24 |
| Total | 83 | 219 | 97 | 399 |
Causes of hospitalizations
There were 265 hospitalizations with hemophilia A and 58 hospitalizations with hemophilia B. Seventy-eight hospitalizations were positive for inhibitor. Cause of most hospitalizations was minor bleeding (Table 1). The median length of hospitalization time was 5 (range 1~745) days. The cost of clotting factor concentrates is a major burden in the economic management of in-patients with hemophilia . Total cost in a single hospitalization of hemophilia A is about twice as much as hemophilia B. Expenditure of drugs in hemophilia A is two to three times more than that of hemophilia B. Total cost and drug cost in hospitalizations of patients with inhibitors were about two times more than these without. When normalized by weight, total cost of non-adults was significantly higher than adults (P=0.002). The positive rates were 1.8% for hepatitis B virus and 12.7% for hepatitis C virus in 283 hospitalizations screened for blood-borne infections.
Conclusions: For hemophilia, the main factor of cost during hospitalization is clotting factor concentrates. Diagnosed with hemophilia A and inhibitor positive increase the global cost.
To cite this abstract in AMA style:
Qu C, Xue F, Liu W, Chen L, Zhang L, Yang R. Analysis of Hospitalization Factors of Hemophilia: 12 Years of Experience in a Single Center [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/analysis-of-hospitalization-factors-of-hemophilia-12-years-of-experience-in-a-single-center/. Accessed December 8, 2021.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/analysis-of-hospitalization-factors-of-hemophilia-12-years-of-experience-in-a-single-center/